Clinical Trials Logo

Clinical Trial Summary

Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. The study will prospectively enroll 75 patients with benign and low-grade brain tumors who will undergo partial brain RT, with either conventionally fractionated or hypofractionated schedules. Subjects will receive MRI scans at baseline, 6 months, and 12 months. Given the role of the limbic system in key cognitive functions affected by RT, researchers have a particular interest in characterizing MRI changes in the limbic system and thalamus in relation to memory and related processes. Specific Aims: 1. To examine objective neurocognitive changes over time. The investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT. 2. To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators specifically hypothesize that comapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT. 3. To examine the relationship between MRI changes for key neuroanatomic structures identified in Aim 1 with objective neurocognitive testing. The investigators hypothesize that cognitive decline will be correlated with damage revealed by MRI to limbic and thalamic structures. This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes.


Clinical Trial Description

Cranial radiation therapy (RT), commonly used to treat benign and malignant brain tumors, can lead to cognitive impairments in domains not related to neuroanatomic structures directly impacted by the tumor. This suggests that off-target RT, even at low doses, may have a negative cognitive impact by affecting neuroanatomic targets proximal or distal to the tumor. While constraints to minimize brain necrosis, ototoxicity, and optic neuropathy are well-established, RT dose tolerances for cognitive changes in key domains (memory, attention, executive function, and processing speed) that occur in RT-treated patients are poorly characterized. There is accumulating evidence that consideration of neuroanatomic targets could better explain cranial RT-mediated cognitive change. Additionally, a recent cooperative group phase III trial has shown that conformal avoidance of the hippocampus with whole brain RT can reduce cognitive impairment. Unfortunately, 60% of patients still had cognitive impairment at 6 months even with hippocampal avoidance, implying that other structures and networks are involved in cognitive deficits from RT and efforts to identify those structures are warranted. A major obstacle in the field has been difficulty identifying sites of off-target tissue damage that could impact cognition after RT. Given the role of the limbic system in key cognitive functions affected by RT, the investigators have a particular interest in characterizing changes in limbic system and thalamus in relation to memory and related processes. The investigators plan to examine RT effects on neuroanatomic structures in the limbic system and thalamus as well as candidate structures identified systematically using magnetic resonance imaging (MRI). The investigators propose to prospectively enroll 75 patients with benign and low-grade brain tumors who will undergo partial brain RT, either conventionally fractionated or hypofractionated. Neurocognitive testing will be obtained at baseline, 3, 6, and 12 months after RT using a battery of tests to assess visual and verbal memory, attention, executive function, and processing speed. Brain MRI, including high resolution T1 images, diffusion tensor imaging (DTI), and resting functional MRI (fMRI) sequences, will be evaluated at baseline, 6, and 12 months after RT. This pilot study will provide preliminary data to identify key areas impacted by RT that can be followed up in future research. Aim 1: To examine objective neurocognitive changes over time. Based on prior data, the investigators hypothesize that they will see RT-induced neurocognitive impairment in up to 50% of patients after cranial RT. The investigators will evaluate neurocognitive testing changes in the HVLT-R delayed recall (verbal memory) as their primary endpoint. As a secondary endpoint, they will evaluate a composite global deficit z-score as well as changes in cognitive domains of visual memory, attention, executive function and processing speed. Aim 2: To examine changes in brain tissue (via MRI) induced by off-target RT in patients with benign and low-grade brain tumors. The investigators hypothesize that a detailed brain tissue injury mapping of off-target RT doses from pre to post-RT and reconstructed structural and functional connectivity (DTI and fMRI) will provide data on the relationship between RT dose and MRI changes in specific structures. The investigators specifically hypothesize that co-mapping of RT dose and MRI changes in the thalamus and limbic system (i.e., thalamic nuclei, hippocampus, fornix, hypothalamus/mammillary bodies, limbic lobe, cingulum) will be most distorted by off-target RT. Aim 3: To examine the relationship between MRI changes for key neuroanatomic structures with neurocognitive testing. The investigators hypothesize that RT will impact several neuronal networks sub-serving multiple cognitive domains and cognitive decline (Aim 2) will be correlated with damage revealed by MRI to limbic and thalamic structures (Aim 1). This approach will allow identification of brain structures most associated with domain-specific cognitive impairment. There is critical need for well-designed longitudinal studies that examine the impact of RT on neuroanatomic structures. Many of the studies that evaluate cognition with RT do not take into account neuroanatomic dose distributions. Even within the literature that evaluates neuroanatomic targets, there has not been a systematic approach to evaluation of neuroanatomic targets by RT. This research will help to define which neuroanatomic structures are most at risk from RT-induced damage and will help ultimately establish new dose constraint guidelines for important structures to improve cognitive outcomes. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04390906
Study type Observational
Source University of Rochester
Contact Sara J Hardy, MD
Phone 585-275-9990
Email sara_hardy@urmc.rochester.edu
Status Recruiting
Phase
Start date October 16, 2018
Completion date January 1, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05298995 - GD2-CAR T Cells for Pediatric Brain Tumours Phase 1
Completed NCT02599142 - Comparing Immobilisation Shells in Cranial Radiotherapy N/A
Not yet recruiting NCT04113278 - Role of Fibirnogen Like Protein 2 as Aprognostic Factor in High Grade Glioma
Enrolling by invitation NCT06391294 - Neuronal and Network Mechanisms of Electrocortical Stimulation
Active, not recruiting NCT05832450 - Predictive Model to Calculate the Risk of RBC Transfusion in Elective Brain Tumours Resections (TScoreBTR)
Recruiting NCT03213002 - Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM Phase 1/Phase 2
Recruiting NCT03067467 - Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)
Recruiting NCT04468919 - Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit N/A
Recruiting NCT04742231 - Handheld Dynamometer During Awake Craniotomy Pilot N/A
Recruiting NCT04725032 - Effects of Intravenous Anesthesia and Balanced Anesthesia on Flash Visual Evoked Potentials N/A
Recruiting NCT03542409 - Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas N/A
Active, not recruiting NCT04165941 - Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma Phase 1
Completed NCT03731455 - WISE Cortical Strip for Intraoperative Neurophysiological Monitoring N/A
Suspended NCT05169944 - Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors Phase 1